As of November 14, 2026, CNS Pharmaceuticals, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 17, 2026 to May 4, 2026 (Form 8-K, May 4, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like CNS Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-04
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-02
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-17
CNS Pharmaceuticals, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-17 to 2026-05-04. Every row below is cited to the filing it comes from, and this page adds each new change as CNS Pharmaceuticals, Inc. files it.
Also on the record for CNS Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Ikarian Capital, LLC | 9.9% of the class | 5%+ stakes | Source |
| May 19, 2026 | Form D, private offering | $22.52M sold | Form D page | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Stonepine Capital Management, LLC | 9.9% of the class | 5%+ stakes | Source |
| April 17, 2026 | Stake report, Schedule 13G, by Ikarian Capital, LLC | 5.7% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Stonepine Capital Management, LLC | 7.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13G, by Stonepine Capital Management, LLC | 5.6% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs CNS Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on CNS Pharmaceuticals, Inc. and the records around it.
CNS Pharmaceuticals, Inc. elsewhere on the record
- Form D filing May 2026
- Who owns it
Companies that share a holder
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), Edesa Biotech, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Connect Biopharma Holdings Limited (Aug 2026), Galera Therapeutics, Inc. (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch CNS Pharmaceuticals, Inc.
Get an email when CNS Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CNS Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on CNS Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CNS Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-04 | Reported | not named in the filing | 8-K, 2026-05-04 | ||
| 2026-03-02 | Reported | not named in the filing | 8-K, 2026-03-02 | ||
| 2026-02-17 | Reported | not named in the filing | 8-K, 2026-02-17 |
New leaders reset buying decisions — get the Full Report on CNS Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at CNS Pharmaceuticals, Inc., with the record behind each one.
Find candidates like senior executive at CNS Pharmaceuticals, Inc.Every change, in the filing's words
Reported
On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company's Board of Directors (the "Board") .
- Mr. Gumulka's resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- On May 4, 2026, the Board agreed to appoint Michal Fisher as an independent member of the Company's Board.
- Ms. Fisher is a senior life sciences executive with over 15 years of experience spanning business development, corporate strategy, investor relations, and deal structuring across biotech, pharma, and medtech.
- She has a proven track record of closing complex licensing transactions, raising capital, and building global partnerships.
- Ms. Fisher is currently Chief Business Officer at BioGenCell, a biotechnology company developing an autologous cell therapy for no-option Critical Limb-Threatening Ischemia, where she leads BioGenCell's capital raising strategy to support a Phase 3 trial as well as commercial planning.
- From 2020 to 2025, Ms. Fisher was Head of Corporate Development at LifeSci Partners, an integrated life sciences advisory firm, where she supported business development and growth of the entire LifeSci Partners platform, including LifeSci Advisors, LifeSci Capital, LifeSci Ventures, LifeSci Consulting, and LifeSci Search.
Reported
On February 26, 2026, CNS Pharmaceuticals, Inc. (the "Company") entered into an employment agreement (the "Employment Agreement") with Lynne Kelley to serve as the Company's Chief Medical Officer effective March 2, 2026.
- The Employment Agreement provides for an initial annual base salary of $450,000, eligibility for an annual bonus with a target equal to 40% of base salary based on goals approved by the Compensation Committee, and eligibility for annual equity grants under the Company's stock incentive plans, in each case as determined by the Compensation Committee of the Board of Directors.
- The Employment Agreement also provides for an initial grant of 9,500 restricted stock units, vesting as follows: 25% on the six-month anniversary of the effective date, 25% on the twelve-month anniversary of the effective date, and the remaining 50% in twelve quarterly installments thereafter, subject to continued employment.
- Dr. Kelley is entitled to participate in the Company's benefit plans and programs for similarly situated executives, expense reimbursement in accordance with Company policy, and other standard benefits.
- Dr. Kelley, age 63, most recently served as Chief Medical Officer of Tissium, Inc., a clinical-stage biotechnology company, from September 2024 to February 2026.
- From May 2022 to February 2026, Dr. Kelley served as Founder and Chief Executive Officer and Chief Medical Officer of Xenthera, Inc., a clinical-stage oncology company, and continues to serve as an advisor for the assets.
Reported
On February 10, 2026, CNS Pharmaceuticals, Inc. (the "Company") entered into an employment agreement (the "O'Loughlin Employment Agreement") with Steve O'Loughlin to serve as the Company's Chief Financial Officer effective March 2, 2026.
- The O'Loughlin Employment Agreement provides for an initial annual base salary of $450,000, eligibility for an annual bonus with a target equal to 40% of base salary based on goals approved by the Compensation Committee, and eligibility for annual equity grants under the Company's stock incentive plans, in each case as determined by the Compensation Committee of the Board of Directors.
- The O'Loughlin Employment Agreement also provides for an initial grant of 9,500 restricted stock units, vesting as follows: 25% on the six-month anniversary of the effective date, 25% on the twelve-month anniversary of the effective date, and the remaining 50% in twelve quarterly installments thereafter, subject to continued employment.
- Mr. O'Loughlin is entitled to participate in the Company's benefit plans and programs for similarly situated executives, expense reimbursement in accordance with Company policy, and other standard benefits.
- Mr. O'Loughlin, age 41, served as Chief Financial Officer of Actinium Pharmaceuticals, Inc. from August 2020 until February 2026, and as its Principal Financial Officer from May 2017 to August 2020.
- Mr. O'Loughlin joined Actinium Pharmaceuticals, Inc. in October 2015 as Vice President, Finance and Corporate Development.
Tools for this story
Each opens in a new tab, filled in for CNS Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
